Integra Therapeutics, a global leader in creating next-generation gene writing tools to make advanced therapies safer and more effective, will present positive data from ex vivo and in vivo preclinical studies that demonstrates the potential of its FiCAT gene-writing platform for developing advanced therapies in the field of paediatric hepatology at the Advanced Therapies Europe congress, taking place in Estoril (Portugal) from 5 to 7 September.
Dr Avencia Sánchez-Mejías, CEO and co-founder of Integra Therapeutics, will analyse the data in a conference titled “FiCAT Innovative Gene Writing Platform for Advanced Therapies” on 7 September at 10:30 am local time, as part of a panel on innovative technologies as a driving force for successful commercialisation of cell and gene therapies on the European market.
Backed by a team of talented researchers, Integra Therapeutics has built a solid technology platform that can write large and small genes, combining the precision of the CRISPR-Cas9 technique and the efficient cargo transfer of a programmable PiggyBac transposon. FiCAT has been tested for ex vivo cell engineering and in vivo gene therapy.
“The ex vivo and in vivo preclinical data validates our FiCAT gene-writing platform for developing cell and gene therapies for patients with genetic minority and oncological diseases and is driving us to intensify our efforts to move into the preclinical regulatory phase in the coming months,” explains Avencia Sánchez-Mejías.
The company continues to expand FiCAT with tools like more effective alternative transposons and programmable nucleases thanks to its high-performance system to detect improved genome editors, along with protein design using artificial intelligence, in order to make gene writing safer and more flexible, efficient and broadly applicable.
About FiCAT (Find and Cut-And-Transfer)
See video: https://youtu.be/oRdwnFt20hg?feature=shared
See website: https://integra-tx.com/gene-writing-platform/
About Integra Therapeutics
Integra Therapeutics is a biotechnology company that is creating next-generation gene writing tools to make advanced therapies safer and more effective. The company was founded in 2020 as a spin-off of Pompeu Fabra University (UPF) by Dr Marc Güell and Dr Avencia Sánchez-Mejías and is based at the Barcelona Biomedical Research Park (PRBB). It is supported by international investors (AdBio Partners, Columbus Venture Partners, Invivo Capital and Takeda Ventures) and organizations in the healthcare and biomedicine sector. In 2023 it has obtained the My green lab sustainability certification. More information: integra-tx.com
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Researchers have confirmed that patients with NK lymphocytes present i...
